Mkts

Protagonist Therapeutics, Inc.

NASDAQ: PTGX
$134.97+2.93 (+2.22%)
As of Nov 9, 10:00 AM ET

Key statistics

Day range
131.31135.01
52-week range
76.70160.81
Today
Open133.54
Previous close134.97
Volume—
Valuation
Market cap8.62B
P/E ratio103.95×
EPS (TTM)1.04
Income & risk
Dividend / yield—
Beta1.24
Avg volume661.1K
Discussion

PTGX News

Stories mentioning PTGX from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue
Cost of Goods Sold
Gross Profit0.000.000.000.000.000.000.000.00
Operating Expenses
Research & Development46,73946,35840,00337,03635,89334,90435,97033,520
Sales General & Admin
Total Operating Expenses60,01657,79251,13347,58747,63143,85846,12842,960
Operating Income (Loss)(3,648)(50,355)(46,421)(42,041)(19,310)126,780(41,453)(38,793)
Interest Income5,8766,7617,0497,4067,5736,8537,6827,404
Interest Expense
Other Expense53.00(124.00)33.0036.0082.0031.00141.0097.00
Pretax Income2,281(43,718)(39,339)(34,599)(11,655)133,664(33,630)(31,292)
Tax Provision(1,502)666.000.00172.000.001,990(420.00)(676.00)
Net Income (Loss)3,783(44,384)(39,339)(34,771)(11,655)131,674(33,210)(30,616)
Earnings Per Share (Basic)0.06(0.70)(0.62)(0.55)(0.19)2.14(0.54)(0.50)
Earnings Per Share (Diluted)0.05(0.70)(0.62)(0.55)(0.19)2.02(0.54)(0.50)
Weighted Average Shares Outstanding (Basic)65,08863,57363,77263,51162,96461,56761,76861,305
Weighted Average Shares Outstanding (Diluted)70,49363,57363,77263,51162,96465,07861,76861,305

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About PTGX

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a stock listed on the Nasdaq Stock Market under the ticker symbol PTGX. It last traded at $134.97 (Nov 9, 2026, 10:00 AM ET), up 2.2% on the day. That gives Protagonist Therapeutics a market capitalisation of $8.6B and a price-to-earnings ratio of 104.0.

Over the past 52 weeks PTGX has traded between $76.70 and $160.81.

Net income for the quarter ended Mar 31, 2026 was $3.8M.

Last 4 quarters
Quarter endedRevenueNet income
Mar 31, 2026—$3.8M
Dec 31, 2025—-$44.4M
Sep 30, 2025—-$39.3M
Jun 30, 2025—-$34.8M

From Protagonist Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…